Industry Trend Analysis - PhRMA Highlights Market Access Barriers And Intellectual Property Concerns - AUG 2014

BMI View: The Russia n government will continue its ambivalent policy towards foreign drugmakers as it seeks to assert control over the industry, and promote the domestic pharmaceutical sector. Incentives will continue to be given to localise d production, but discriminatory legislation will ensure local companies ' advantages over their foreign competitors .

The Pharmaceutical Research & Manufacturers Association of America (PhRMA) has highlighted Russia as a country with serious intellectual property and market access barriers in its annual submission to the office of the US Trade Representative (USTR). Concerns over data protection, patent enforcement, government drug pricing, local procurement rules and clinical trial requirements have persisted among PhRMA members operating in Russia, leading to its designation as a Watch List country.

Areas Of Concern

Shifting Macroeconomic Fundamentals Impact Long Term Outlook
Russian Pharmaceutical Sales, US$bn

This article is part of our Western Europe coverage. To access this article subscribe now or sign up for free trial